in5points
FinanceAsianet Newsable

OMER Stock Gains 4% — CMS Green-Lights $287K Add-On Payments For Transplant Drug

in5points

  1. Starting October 1, hospitals can receive up to about $287,000 more from Medicare for each qualifying patient for Yartemlea.

  2. CMS approved the add-on payments for the transplant drug Yartemlea.

  3. Omeros announced the CMS decision, which will increase Medicare reimbursement for Yartemlea.

4h ago · original ↗
OMER Stock Gains 4% — CMS Green-Lights $287K Add-On Payments For Transplant Drug · in5points